4.7 Article

Sirt1 activation prevents anti-Thy 1.1 mesangial proliferative glomerulonephritis in the rat through the Nrf2/ARE pathway

期刊

EUROPEAN JOURNAL OF PHARMACOLOGY
卷 832, 期 -, 页码 138-144

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2018.05.017

关键词

MsPGN; Sirt1; Nrf2-ARE anti-oxidative pathway

资金

  1. Medical Scientific Research Foundation of Guangdong Province, China [A2015325]
  2. National Natural Foundation of China [81603168]
  3. Natural Science Foundation of Guangdong Province, China [2016A030310152, 2016A030310459, 2017A030313678]
  4. Science and Technology Planning Project of Guangdong Province, China [2016A020215219]
  5. Administration of Traditional Chinese Medicine of Guangdong Province, China [20171052]

向作者/读者索取更多资源

Mesangial proliferative glomerulonephritis (MsPGN) is characterized by glomerular mesangial cells proliferation and extracellular matrix deposition in mesangial area, which develop into glomerulosclerosis. Both silent information regulator 2-related protein 1 (Sirt1) and nuclear factor erythroid 2-related factor 2/anti-oxidant response element (Nrf2/ARE) pathway had remarkable renoprotective effects. However, whether Sirt1 and Nrf2/ ARE pathway can regulate the pathological process of MsPGN remains unknown. Here, we found that Sirt1 activation by SRT1720 decreased mesangial hypercellularity and mesangial matrix areas, reduced renal Co14 and alpha-SMA expressions, lowered 24 h proteinuria, and eventually reduced FN and TGF-beta 1 expressions in rats received anti-Thy 1.1 IgG. Further study showed that SRT1720 markedly enhanced the activity of Nrf2/ARE pathway including promoting the nuclear content and ARE-binding ability of Nrf2, elevating the protein levels of HO-1 and SOD1, two target genes of Nrf2, which eventually increased total SOD activity and decreased malondialdehyde level in the kidney tissues of experimental anti-Thy 1.1 MsPGN rats. Taken together, Sir1l prevented the pathological process of experimental anti-Thy 1.1 MsPGN through promoting the activation of Nrf2/ ARE pathway, which warrants further elucidation. Sir1l might be a potential therapeutic target for treating MsPGN.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据